WO2005089744A3 - Use of docosatrienes, resolvins and their stable analogs in the treatment of airway diseases and asthma - Google Patents

Use of docosatrienes, resolvins and their stable analogs in the treatment of airway diseases and asthma Download PDF

Info

Publication number
WO2005089744A3
WO2005089744A3 PCT/US2005/009056 US2005009056W WO2005089744A3 WO 2005089744 A3 WO2005089744 A3 WO 2005089744A3 US 2005009056 W US2005009056 W US 2005009056W WO 2005089744 A3 WO2005089744 A3 WO 2005089744A3
Authority
WO
WIPO (PCT)
Prior art keywords
resolvins
dha
epa
present
compounds
Prior art date
Application number
PCT/US2005/009056
Other languages
French (fr)
Other versions
WO2005089744A2 (en
Inventor
Charles N Serhan
Bruce D Levy
Original Assignee
Brigham & Womens Hospital
Charles N Serhan
Bruce D Levy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham & Womens Hospital, Charles N Serhan, Bruce D Levy filed Critical Brigham & Womens Hospital
Priority to EP05735088A priority Critical patent/EP1725228A2/en
Priority to AU2005222706A priority patent/AU2005222706B2/en
Publication of WO2005089744A2 publication Critical patent/WO2005089744A2/en
Publication of WO2005089744A3 publication Critical patent/WO2005089744A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
    • C07C59/48—Unsaturated compounds containing hydroxy or O-metal groups containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages

Abstract

The present invention is generally drawn to novel isolated therapeutic agents, termed resolvins, generated from the interaction between a dietary omega-3 polyunsaturated fatty acid (PUFA) such as eicosapentaenoic acid (EPA) or docosahexaenoic acid (DHA), cyclooxygenase­II (COX-2) and an analgesic, such as aspirin (ASA). Surprisingly, careful ;isolation of compounds generated from the combination of components in an appropriate environment provide di- and tri-hydroxy EPA or DHA compounds having unique structural and physiological properties. The present invention therefore provides for many new useful therapeutic di- or tri­hydroxy derivatives of EPA or DHA (resolvins) that diminish, prevent, or eliminate inflammation or PMN migration, for example. The present invention also provides methods of use, methods of preparation, and packaged pharmaceuticals for use as medicaments for the compounds disclosed throughout the specification.
PCT/US2005/009056 2004-03-17 2005-03-17 Use of docosatrienes, resolvins and their stable analogs in the treatment of airway diseases and asthma WO2005089744A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP05735088A EP1725228A2 (en) 2004-03-17 2005-03-17 Use of docosatrienes, resolvins and their stable analogs in the treatment of airway diseases and asthma
AU2005222706A AU2005222706B2 (en) 2004-03-17 2005-03-17 Use of docosatrienes, resolvins and their stable analogs in the treatment of airway diseases and asthma

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US55391804P 2004-03-17 2004-03-17
US60/553,918 2004-03-17
US11/081,203 2005-03-16
US11/081,203 US7759395B2 (en) 2002-08-12 2005-03-16 Use of docosatrienes, resolvins and their stable analogs in the treatment of airway diseases and asthma

Publications (2)

Publication Number Publication Date
WO2005089744A2 WO2005089744A2 (en) 2005-09-29
WO2005089744A3 true WO2005089744A3 (en) 2006-01-12

Family

ID=34968509

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/009056 WO2005089744A2 (en) 2004-03-17 2005-03-17 Use of docosatrienes, resolvins and their stable analogs in the treatment of airway diseases and asthma

Country Status (4)

Country Link
US (4) US7759395B2 (en)
EP (1) EP1725228A2 (en)
AU (2) AU2005222706B2 (en)
WO (1) WO2005089744A2 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8349896B2 (en) 2000-02-16 2013-01-08 The Brigham And Womens's Hospital, Inc. Aspirin-triggered lipid mediators
US8461201B2 (en) 2002-04-01 2013-06-11 University Of Southern California Trihydroxy polyunsaturated eicosanoid derivatives
US8481772B2 (en) 2002-04-01 2013-07-09 University Of Southern California Trihydroxy polyunsaturated eicosanoid derivatives
US9364454B2 (en) 2005-10-03 2016-06-14 The Brigham And Women's Hospital, Inc. Anti-inflammatory actions of neuroprotectin D1/protectin D1 and its natural stereoisomers

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7030159B2 (en) * 2001-12-18 2006-04-18 The Brigham And Women's Hospital, Inc. Approach to anti-microbial host defense with molecular shields with EPA and DHA analogs
US7582785B2 (en) * 2002-04-01 2009-09-01 University Of Southern California Trihydroxy polyunsaturated eicosanoid derivatives
US7759395B2 (en) 2002-08-12 2010-07-20 The Brigham And Women's Hospital, Inc. Use of docosatrienes, resolvins and their stable analogs in the treatment of airway diseases and asthma
AU2003258194B2 (en) * 2002-08-12 2009-11-12 The Brigham And Women's Hospital, Inc. Resolvins: biotemplates for therapeutic interventions
WO2004078143A2 (en) * 2003-03-05 2004-09-16 The Brigham And Women's Hospital Inc. Methods for identification and uses of anti-inflammatory receptors for eicosapentaenoic acid analogs
EP1755537A4 (en) * 2004-04-14 2009-12-09 Univ Boston Methods and compositions for preventing or treating periodontal diseases
US20060293288A1 (en) * 2005-01-07 2006-12-28 Serhan Charles N Use of resolvins to treat gastrointestinal diseases
EP1946754A4 (en) * 2005-10-24 2009-04-22 Biopharma Norge As Pronova Therapeutic agent for ulcerative colitis and/or crohn's disease
US10042980B2 (en) 2005-11-17 2018-08-07 Gearbox Llc Providing assistance related to health
US20070112796A1 (en) 2005-11-17 2007-05-17 Jung Edward K Research in providing assistance related to health
US8532938B2 (en) 2005-11-17 2013-09-10 The Invention Science Fund I, Llc Testing-dependent administration of a nutraceutical
US20070112592A1 (en) 2005-11-17 2007-05-17 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Payments in providing assistance related to health
WO2007061783A1 (en) * 2005-11-18 2007-05-31 Trustees Of Boston University Treatment and prevention of bone loss using resolvins
US10296720B2 (en) 2005-11-30 2019-05-21 Gearbox Llc Computational systems and methods related to nutraceuticals
US8000981B2 (en) 2005-11-30 2011-08-16 The Invention Science Fund I, Llc Methods and systems related to receiving nutraceutical associated information
US8068991B2 (en) 2005-11-30 2011-11-29 The Invention Science Fund I, Llc Systems and methods for transmitting pathogen related information and responding
US8297028B2 (en) 2006-06-14 2012-10-30 The Invention Science Fund I, Llc Individualized pharmaceutical selection and packaging
US7974856B2 (en) 2005-11-30 2011-07-05 The Invention Science Fund I, Llc Computational systems and methods related to nutraceuticals
US7827042B2 (en) 2005-11-30 2010-11-02 The Invention Science Fund I, Inc Methods and systems related to transmission of nutraceutical associated information
US7927787B2 (en) 2006-06-28 2011-04-19 The Invention Science Fund I, Llc Methods and systems for analysis of nutraceutical associated components
US8340944B2 (en) 2005-11-30 2012-12-25 The Invention Science Fund I, Llc Computational and/or control systems and methods related to nutraceutical agent selection and dosing
WO2007075378A2 (en) * 2005-12-20 2007-07-05 Searete Llc Control systems for individualized pharmaceutical and nutraceutical selection and packaging
AU2007243282A1 (en) * 2006-04-28 2007-11-08 Resolvyx Pharmaceuticals, Inc. Compositions and methods for the treatment of cardiovascular disease
US20070299695A1 (en) * 2006-06-23 2007-12-27 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Customized visual marking for medication labeling
KR20090040323A (en) * 2006-07-19 2009-04-23 레솔빅스 파마슈티칼즈, 인코퍼레이티드 Compositions and methods for the treatment of mucositis
JP4656658B2 (en) * 2006-08-22 2011-03-23 株式会社ユニバーサルエンターテインメント Banknote handling equipment
WO2008063772A2 (en) * 2006-10-13 2008-05-29 The Brigham And Women's Hospital Inc. Resolvin d series and protectin d1 mitigate acute kidney injury
US20080161274A1 (en) * 2006-10-26 2008-07-03 Resolvyx Pharmaceuticals, Inc. Compounds and methods for inhibition of bone loss
US20080161275A1 (en) * 2006-12-05 2008-07-03 Resolvyx Pharmaceuticals, Inc. Compositions and methods for the treatment of inflammatory disease
US8263651B2 (en) * 2006-12-15 2012-09-11 The Regents Of The University Of California Use of cis-epoxyeicosatrienoic acids and inhibitors of soluble epoxide hydrolase to treat conditions mediated by PBR, CB2, and NK2 receptors
WO2008119146A2 (en) * 2007-03-29 2008-10-09 Dair, Bicudo Piai Combi-preparation of phosphoethanolamine and omega-3-fatty acid for treating bronchial asthma and copd
US8001345B2 (en) * 2007-05-10 2011-08-16 Dot Hill Systems Corporation Automatic triggering of backing store re-initialization
WO2009017802A1 (en) 2007-08-01 2009-02-05 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Nitro-fattyacid modulation of type ii diabetes
JP2010539167A (en) * 2007-09-14 2010-12-16 リゾルヴィクス・ファーマシューティカルズ・インコーポレイテッド Compositions and methods for modulating immune function
JP5421272B2 (en) * 2007-10-12 2014-02-19 リゾルヴィクス・ファーマシューティカルズ・インコーポレイテッド Compositions and methods for the treatment of eye diseases
WO2009134383A2 (en) 2008-05-01 2009-11-05 Complexa Inc. Vinyl substituted fatty acids
US20140024713A1 (en) 2008-06-19 2014-01-23 University Of Utah Research Foundation Use of nitrated lipids for treatment of side effects of toxic medical therapies
WO2009155439A2 (en) 2008-06-19 2009-12-23 University Of Utah Research Foundation Use of nitrated lipids for treatment of side effects of toxic medical therapies
WO2010005572A2 (en) * 2008-07-09 2010-01-14 The Scripps Research Institute Alpha-keto heterocycles as faah inhibitors
WO2010021385A1 (en) * 2008-08-22 2010-02-25 持田製薬株式会社 Therapeutic agent for anca-related vasculitis
WO2010095706A1 (en) 2009-02-20 2010-08-26 国立大学法人東京大学 Novel anti-inflammatory compounds
EP2459189A4 (en) 2009-07-31 2013-01-16 Univ Pittsburgh Fatty acids as anti-inflammatory agents
US8686167B2 (en) 2009-10-02 2014-04-01 Complexa, Inc. Heteroatom containing substituted fatty acids
WO2011091160A1 (en) * 2010-01-20 2011-07-28 Henry Wu Custom-formulated phospholipid microbubbles and methods and uses thereof
EP2744491B1 (en) 2011-08-19 2020-07-29 The University of Utah Research Foundation Combination therapy with nitrated lipids and inhibitors of the renin-angiotensin-aldosterone system
WO2013116753A1 (en) * 2012-02-03 2013-08-08 University Of Pittsburgh-Of The Commonwelth System Of Higher Education Fatty acids as anti-inflammatory agents
EP2814479B1 (en) 2012-02-15 2019-09-04 Anida Pharma Inc. Methods of treating amyotrophic lateral sclerosis
NZ702325A (en) 2012-05-10 2016-09-30 Solutex Na Llc Oils with anti-inflammatory activity containing natural specialized proresolving mediators and their precursors
PL2887923T3 (en) 2012-08-24 2023-08-14 Sun Pharmaceutical Industries Limited Ophthalmic formulation of polyoxyl lipid or polyoxyl fatty acid and treatment of ocular conditions
WO2014039964A2 (en) 2012-09-10 2014-03-13 The Regents Of The University Of California Compounds and methods for modulating vascular injury
WO2014130894A1 (en) * 2013-02-21 2014-08-28 University Of Southern California Compositions for the treatment of inflammatory diseases
JP6295278B2 (en) 2013-02-28 2018-03-14 アニダ ファーマ インコーポレイテッド How to treat ototoxicity
CA2942050A1 (en) * 2014-03-13 2015-09-17 Barry D. Sears Compositions and methods for reducing chronic low-level inflammation
WO2016133788A1 (en) 2015-02-20 2016-08-25 The Regents Of The University Of California Methods of inhibiting pain
EP3270693B1 (en) 2015-03-18 2021-06-30 Forsyth Dental Infirmary for Children Methods for stabilizing atherosclerotic plaques using lipoxins, resolvins, and analogs thereof
IL280619B2 (en) 2015-07-07 2023-10-01 H Lundbeck As Pde9 inhibitors with imidazo triazinone backbone and imidazo pyrazinone backbone for treatment of peripheral diseases
WO2017041094A1 (en) 2015-09-03 2017-03-09 Solutex Na Llc Compositions comprising omega-3 fatty acids, 17-hdha and 18- hepe and methods of using same
EP3355879A4 (en) 2015-10-02 2019-05-22 Complexa, Inc. Prevention, treatment and reversal of disease using therapeutically effective amounts of activated fatty acids
WO2017077528A2 (en) * 2015-11-02 2017-05-11 Salzman Lovelace Investments, Ltd. Methods and pharmaceutical compositions for treatment of lung inflammation
DK3373976T3 (en) 2015-11-10 2024-04-02 Sun Pharmaceutical Ind Ltd TOPICAL FORMULATIONS AND USES THEREOF
WO2017153977A1 (en) * 2016-03-08 2017-09-14 Salzman Lovelace Investments, Ltd. Solid formulations of resolvins and uses thereof
EP3463419A4 (en) 2016-05-27 2020-03-25 Forsyth Dental Infirmary for Children Compositions and methods of treating cancer using lipid agonists and receptors thereof
ES2827796T3 (en) * 2016-06-03 2021-05-24 Thetis Pharmaceuticals Llc Compositions and procedures related to salts of specialized pro-resolution mediators of inflammation
WO2018161175A1 (en) 2017-03-09 2018-09-13 University Health Network Lipoxin and lipoxin analogue mediated neuroprotection and treatments
WO2019049138A1 (en) * 2017-09-11 2019-03-14 Salzman Investments, Ltd. Methods for synthesis of resolvins
US20230399295A1 (en) * 2020-11-04 2023-12-14 The Brigham And Women's Hospital, Inc. Compositions for increasing tissue regeneration and delaying or reducing granuloma formation
WO2023168245A2 (en) 2022-03-03 2023-09-07 Thetis Pharmaceuticals Llc Cyclodextrin complexes of specialized proresolving mediators
CN115969830A (en) * 2023-02-28 2023-04-18 武汉大学人民医院（湖北省人民医院） Application of protectin D1 in preparation of medicine for relieving and/or treating hypertension and complications thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6428990B1 (en) * 1997-04-11 2002-08-06 Abbott Laboratories Human desaturase gene and uses thereof

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4201211A (en) * 1977-07-12 1980-05-06 Alza Corporation Therapeutic system for administering clonidine transdermally
US4701521A (en) * 1978-07-17 1987-10-20 The Trustees Of Boston University Method of effecting cellular uptake of molecules
GB2033745B (en) 1978-05-26 1983-08-17 Wellcome Found Fatty acid and derivatives thereof for use in treatment or prophylaxis of thromboembolic conditions
US4442099A (en) * 1981-11-27 1984-04-10 Research Corporation Leukotriene analogues
US4567290A (en) * 1981-11-27 1986-01-28 Research Corporation Leukotriene analogues
US4576758A (en) * 1984-06-01 1986-03-18 The Upjohn Company Anti-inflammatory lipoxin B analogs
US4759880A (en) * 1984-09-27 1988-07-26 Research Corporation Alkanoarachidonic acids
GB8507058D0 (en) * 1985-03-19 1985-04-24 Efamol Ltd Pharmaceutical & dietary compositions
US4710521A (en) * 1986-07-25 1987-12-01 The Celotex Corporation Catalyst mixtures for polyisocyanurate foam
US4810424A (en) * 1987-10-09 1989-03-07 The State Of Oregon Acting By And Through The Oregon State Board Of Higher Education On Behalf Of Oregon State University Method for the recovery of 12-(S)-hydroxyeicosapentaenoic acid from the red alga murrayella periclados
US5862399A (en) * 1988-12-28 1999-01-19 Philips Electronics North America Corporation Write control unit
US5136501A (en) * 1989-05-26 1992-08-04 Reuters Limited Anonymous matching system
WO1991016914A1 (en) * 1990-05-07 1991-11-14 Bockow Barry I Methods and preparations of stable, deodorized oils and pharmaceutical compositions thereof
US5650435A (en) * 1991-04-01 1997-07-22 Madara; James L. Modulation of inflammation related to columnar epithelia
US5087790A (en) * 1991-06-12 1992-02-11 University Of Southern California Method for olefination of carbonyl compounds using titanocene derivatives
CA2112399C (en) * 1991-06-24 2004-06-29 Antonio Ferrante Methods and compositions for treating malaria and other diseases
US5177046A (en) * 1991-09-20 1993-01-05 Air Products And Chemicals, Inc. Amine-boron adducts as reduced odor catalyst compositions for the production of polyurethanes
US5409955A (en) * 1993-05-13 1995-04-25 Bockow; Barry I. Compositions and methods for inhibiting uterine contractility
US5441951A (en) * 1994-06-15 1995-08-15 Brigham & Women's Hospital Lipoxin compounds
US6048897A (en) * 1993-06-15 2000-04-11 Brigham And Women's Hospital Lipoxin compounds and their use in treating cell proliferative disorders
US6887901B1 (en) * 1993-06-15 2005-05-03 Brigham & Women's Hospital, Inc. Lipoxin compounds and their use in treating cell proliferative disorders
US5411988A (en) * 1993-10-27 1995-05-02 Bockow; Barry I. Compositions and methods for inhibiting inflammation and adhesion formation
US5814599A (en) * 1995-08-04 1998-09-29 Massachusetts Insitiute Of Technology Transdermal delivery of encapsulated drugs
US6030917A (en) * 1996-07-23 2000-02-29 Symyx Technologies, Inc. Combinatorial synthesis and analysis of organometallic compounds and catalysts
US5752238A (en) * 1994-11-03 1998-05-12 Intel Corporation Consumer-driven electronic information pricing mechanism
US5594732A (en) * 1995-03-03 1997-01-14 Intecom, Incorporated Bridging and signalling subsystems and methods for private and hybrid communications systems including multimedia systems
US5801280A (en) 1995-04-07 1998-09-01 Sumitomo Chemical Company, Limited Processes for preparing optically active alcohols and optically active amines
US5845265A (en) * 1995-04-26 1998-12-01 Mercexchange, L.L.C. Consignment nodes
US5756789A (en) * 1995-06-08 1998-05-26 Texaco, Inc. Synthesis of metal--containing aluminophosphates with layered structure
CA2182851A1 (en) * 1995-08-15 1997-02-16 August Masaru Watanabe Method for treating substance abuse withdrawal
US5709855A (en) * 1995-09-22 1998-01-20 Bockow; Barry I. Compositions of spirulina algae and omega fatty acids for treatment of inflammation and pain
AU1122997A (en) 1995-11-07 1997-06-11 Cadis, Inc. Search engine for remote object oriented database management system
US5870717A (en) * 1995-11-13 1999-02-09 International Business Machines Corporation System for ordering items over computer network using an electronic catalog
US5995943A (en) 1996-04-01 1999-11-30 Sabre Inc. Information aggregation and synthesization system
WO1997038986A1 (en) * 1996-04-12 1997-10-23 G.D. Searle & Co. Substituted benzenesulfonamide derivatives as prodrugs of cox-2 inhibitors
US5878400A (en) * 1996-06-17 1999-03-02 Trilogy Development Group, Inc. Method and apparatus for pricing products in multi-level product and organizational groups
US5842040A (en) * 1996-06-18 1998-11-24 Storage Technology Corporation Policy caching method and apparatus for use in a communication device based on contents of one data unit in a subset of related data units
US6602817B1 (en) * 1998-10-23 2003-08-05 University Of Southern California Combination approach to chiral reagents or catalysts having amine or amino alcohol ligands
CA2259203C (en) * 1996-06-28 2008-04-29 Nicos A. Petasis Method for the synthesis of amines and amino acids with organoboron derivatives
US5890138A (en) * 1996-08-26 1999-03-30 Bid.Com International Inc. Computer auction system
US5861399A (en) 1996-07-17 1999-01-19 Heart Care Partners Methods and compositions for the rapid and enduring relief of inadequate myocardial function
US5896379A (en) * 1996-08-26 1999-04-20 Motorola, Inc. Network node for packet switching with selective data processing and method therefor
US5912006A (en) 1996-08-28 1999-06-15 Eboc, Inc. Compositions and methods for alleviating discomforting menstrual pain
US5946467A (en) 1996-09-20 1999-08-31 Novell, Inc. Application-level, persistent packeting apparatus and method
US20020055539A1 (en) * 1996-10-02 2002-05-09 Bockow Barry I. Compositions and methods for treating cardiovascular conditions
CA2269131A1 (en) 1996-10-25 1998-05-07 Ipf, Inc. System and method for managing and serving consumer product related information over the internet
US6201022B1 (en) * 1997-03-27 2001-03-13 Myorx, Inc. Methods for treating neurotransmitter-mediated pain syndromes by topically administering an omega fatty acid
US6008205A (en) * 1997-04-04 1999-12-28 The Brigham & Women's Hospital, Inc. Polyisoprenyl phosphate stable analogs for regulation of neutrophil responses
AU6959898A (en) * 1997-04-11 1998-11-11 David J. Grainger Compounds and therapies for the prevention of vascular and non-vascular pathol ogies
US5878423A (en) * 1997-04-21 1999-03-02 Bellsouth Corporation Dynamically processing an index to create an ordered set of questions
US6258900B1 (en) * 1998-07-16 2001-07-10 Crystaphase International, Inc Filtration and flow distribution method for chemical reactors
US6006264A (en) 1997-08-01 1999-12-21 Arrowpoint Communications, Inc. Method and system for directing a flow between a client and a server
US6038668A (en) 1997-09-08 2000-03-14 Science Applications International Corporation System, method, and medium for retrieving, organizing, and utilizing networked data
US6030715A (en) * 1997-10-09 2000-02-29 The University Of Southern California Azlactone-related dopants in the emissive layer of an OLED
US6259699B1 (en) * 1997-12-30 2001-07-10 Nexabit Networks, Llc System architecture for and method of processing packets and/or cells in a common switch
JP3196714B2 (en) * 1998-03-05 2001-08-06 日本電気株式会社 Manufacturing method of semiconductor integrated circuit having triple well structure
US5946567A (en) * 1998-03-20 1999-08-31 Taiwan Semiconductor Manufacturing Company, Ltd. Method for making metal capacitors for deep submicrometer processes for semiconductor integrated circuits
JP2002513750A (en) 1998-05-07 2002-05-14 エラン コーポレーシヨン ピーエルシー Solvent / co-solvent free microemulsion and emulsion pre-concentrate drug delivery system
US6377937B1 (en) * 1998-05-28 2002-04-23 Paskowitz Associates Method and system for more effective communication of characteristics data for products and services
US6069109A (en) * 1998-07-01 2000-05-30 Union Carbide Chemicals & Plastics Technology Corporation Process for the production of half-sandwich transition metal based catalyst precursors
US6336138B1 (en) * 1998-08-25 2002-01-01 Hewlett-Packard Company Template-driven approach for generating models on network services
US6336105B1 (en) 1998-11-16 2002-01-01 Trade Access Inc. System and method for representing data and providing electronic non-repudiation in a negotiations system
DE19855426A1 (en) 1998-12-02 2000-06-08 Wolfgang Langhoff Agents for the therapy and prophylaxis of rheumatic-arthritic diseases and for the prophylaxis of cardiovascular diseases
US6272474B1 (en) * 1999-02-08 2001-08-07 Crisostomo B. Garcia Method for monitoring and trading stocks via the internet displaying bid/ask trade bars
US6397212B1 (en) * 1999-03-04 2002-05-28 Peter Biffar Self-learning and self-personalizing knowledge search engine that delivers holistic results
CA2367160A1 (en) * 1999-03-18 2000-09-21 Charles N. Serhan Leukotriene b4 receptor transgenic mammals
CA2747376A1 (en) * 1999-03-18 2000-09-21 Brigham And Women's Hospital Use of lipoxin compounds for inhibiting of tnf-(alpha) initiated neutrophil response
ES2344138T3 (en) * 1999-03-18 2010-08-19 The Brigham And Women's Hospital, Inc. 16-PHENOXY-LIPOXINE ANALOGS FOR MEDICAL USE.
ATE303355T1 (en) * 1999-03-18 2005-09-15 Brigham & Womens Hospital LIPOXIN COMPOUNDS AND THEIR APPLICATION
US6427132B1 (en) * 1999-08-31 2002-07-30 Accenture Llp System, method and article of manufacture for demonstrating E-commerce capabilities via a simulation on a network
US6415270B1 (en) * 1999-09-03 2002-07-02 Omnihub, Inc. Multiple auction coordination method and system
ATE344226T1 (en) * 2000-02-16 2006-11-15 Brigham & Womens Hospital ASPIRIN-RELEASED LIPID MEDIATORS
WO2001070664A2 (en) * 2000-03-20 2001-09-27 Trustees Of Boston University Lipoxin analogs and methods for the treatment of periodontal disease
US6653776B1 (en) * 2000-06-28 2003-11-25 International Business Machines Corporation Discrete magnets in dielectric forming metal/ceramic laminate and process thereof
JP2005508282A (en) * 2001-03-02 2005-03-31 ザ・ブリガム・アンド・ウイメンズ・ホスピタル Lipoxin analogues as novel angiogenesis inhibitors
EP1441715B1 (en) * 2001-11-06 2013-02-27 The Brigham And Women's Hospital, Inc. Lipoxins and aspirin-triggered lipoxins and their stable analogs in the treatment of asthma and inflammatory airway diseases
US20030195248A1 (en) * 2001-12-18 2003-10-16 Serhan Charles N. Novel approach to anti-microbial host defense with molecular shields with lipoxin compounds
US7030159B2 (en) 2001-12-18 2006-04-18 The Brigham And Women's Hospital, Inc. Approach to anti-microbial host defense with molecular shields with EPA and DHA analogs
EP1528909A4 (en) 2002-04-01 2006-05-24 Univ Southern California Trihydroxy polyunsaturated eicosanoids
US7582785B2 (en) * 2002-04-01 2009-09-01 University Of Southern California Trihydroxy polyunsaturated eicosanoid derivatives
AU2003238240A1 (en) * 2002-06-17 2003-12-31 Resolvyx Pharmaceuticals ANALOGUES OF LIPID MEDIATORS DERIVED FROM OMEGA-3 PUFAs AND METHODS OF USE
US7759395B2 (en) * 2002-08-12 2010-07-20 The Brigham And Women's Hospital, Inc. Use of docosatrienes, resolvins and their stable analogs in the treatment of airway diseases and asthma
AU2003258194B2 (en) 2002-08-12 2009-11-12 The Brigham And Women's Hospital, Inc. Resolvins: biotemplates for therapeutic interventions
WO2004078143A2 (en) 2003-03-05 2004-09-16 The Brigham And Women's Hospital Inc. Methods for identification and uses of anti-inflammatory receptors for eicosapentaenoic acid analogs
EP1660069A4 (en) * 2003-08-05 2009-03-18 Univ Louisiana State Neuroprotection protects against cellular apoptosis, neural stroke damage, alzheimer's disease and retinal degeneration
US20060293288A1 (en) * 2005-01-07 2006-12-28 Serhan Charles N Use of resolvins to treat gastrointestinal diseases
JP5186342B2 (en) 2008-11-28 2013-04-17 インターナショナル・ビジネス・マシーンズ・コーポレーション Information processing apparatus, information processing method, and program

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6428990B1 (en) * 1997-04-11 2002-08-06 Abbott Laboratories Human desaturase gene and uses thereof

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
MARCHESELLI V L ET AL: "Novel Docosanoids Inhibit Brain Ischemia-Reperfusion-mediated Leukocyte Infiltration and Pro-inflammatory Gene Expression", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 278, no. 44, 31 October 2003 (2003-10-31), pages 43807 - 43817, XP002267882, ISSN: 0021-9258 *
SERHAN C N ET AL: "Resolvins, docosatrienes, and neuroprotectins, novel omega-3-derived mediators, and their aspirin-triggered endogenous epimers: an overview of their protective roles in catabasis", PROSTAGLANDINS AND OTHER LIPID MEDIATORS, ELSEVIER, vol. 73, no. 3-4, April 2004 (2004-04-01), pages 155 - 172, XP004515307, ISSN: 1098-8823 *
SERHAN C N ET AL: "Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals", JOURNAL OF EXPERIMENTAL MEDICINE, TOKYO, JP, vol. 196, no. 8, 21 October 2002 (2002-10-21), pages 1025 - 1037, XP002267881, ISSN: 0022-1007 *
SERHAN ET AL: "Novel omega - 3-derived local mediators in anti-inflammation and resolution", PHARMACOLOGY AND THERAPEUTICS, ELSEVIER, GB, vol. 105, no. 1, January 2005 (2005-01-01), pages 7 - 21, XP004697813, ISSN: 0163-7258 *
SERHAN, CHARLES N.: "A search for endogenous mechanisms of anti-inflammation uncovers novel chemical mediators: missing links to resolution", HISTOCHEMISTRY AND CELL BIOLOGY, vol. 122, no. 4, 2004, pages 305 - 321, XP002336765 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8349896B2 (en) 2000-02-16 2013-01-08 The Brigham And Womens's Hospital, Inc. Aspirin-triggered lipid mediators
US8461201B2 (en) 2002-04-01 2013-06-11 University Of Southern California Trihydroxy polyunsaturated eicosanoid derivatives
US8481772B2 (en) 2002-04-01 2013-07-09 University Of Southern California Trihydroxy polyunsaturated eicosanoid derivatives
US8802874B2 (en) 2002-04-01 2014-08-12 University Of Southern California Trihydroxy polyunsaturated eicosanoid derivatives
US9364454B2 (en) 2005-10-03 2016-06-14 The Brigham And Women's Hospital, Inc. Anti-inflammatory actions of neuroprotectin D1/protectin D1 and its natural stereoisomers

Also Published As

Publication number Publication date
AU2010200717B2 (en) 2011-06-30
US7759395B2 (en) 2010-07-20
US20050261255A1 (en) 2005-11-24
US8569542B2 (en) 2013-10-29
AU2005222706A1 (en) 2005-09-29
US20080096961A1 (en) 2008-04-24
US8933270B2 (en) 2015-01-13
US7872152B2 (en) 2011-01-18
US20140179630A1 (en) 2014-06-26
AU2010200717A1 (en) 2010-03-18
EP1725228A2 (en) 2006-11-29
AU2005222706B2 (en) 2010-02-18
WO2005089744A2 (en) 2005-09-29
US20120264713A1 (en) 2012-10-18

Similar Documents

Publication Publication Date Title
WO2005089744A3 (en) Use of docosatrienes, resolvins and their stable analogs in the treatment of airway diseases and asthma
WO2004014835A3 (en) Resolvins: biotemplates for therapeutic interventions
WO2006078457A3 (en) Use of resolvins to treat gastrointestinal diseases
EP1392276B1 (en) Potentiation of therapeutic effects of polyunsaturated fatty acids
Kaur et al. Essential fatty acids as functional components of foods-a review
EP1390025B1 (en) Use of coenzyme q (ubiquinone) and eicosapentaenoic acid (epa) for the treatment of non-hodgkin&#39;s lymphoma and psychiatric or neurological disorders
Fialkow Omega-3 fatty acid formulations in cardiovascular disease: dietary supplements are not substitutes for prescription products
CA2748743C (en) Dietary supplements comprising activated fatty acids
US5178873A (en) Essential fatty acid treatment
CA2411368C (en) Therapeutic combinations of fatty acids
WO2009091538A3 (en) Pharmaceutical composition comprising epa and dha for treating hypertriglyceridemia and hypercholesterolemia
KR940018091A (en) Prescriptions Containing Unsaturated Fatty Acids
HUP0303019A2 (en) Use of pharmaceutical compositions containing essential n-3 fatty acids in cardiac insufficiency and heart failure therapy
JP2022542513A (en) Preparations containing omega-3 fatty acid salts and extracts of gum resins from Boswellia species
EP2994165A1 (en) Nutritional or dietary supplements containing fatty acids and nitrite
JP2006503031A5 (en)
JP2016501248A5 (en)
AU625705B2 (en) Pharmaceutical and dietary uses of fatty acids
ITFI20080243A1 (en) FORMULATIONS FOR ORAL ADMINISTRATION OF OMEGA POLIENOIC FATTY ACIDS IN COMBINATION WITH NATURAL OR SEMI-SYNTHETIC STATINES.
Hr Omega-3-Fatty Acids: Cardiovascular Disease
JP4960087B2 (en) Combinations of vascular protective substances and formulations containing them
Eritsland et al. Effects of highly concentrated omega-3 polyunsaturated fatty acids and acetylsalicylic acid, alone and combined, on bleeding time and serum lipid profile
Afroze et al. Potentials of omega-3 fatty acids as therapeutic drugs and its obstacles in the pathway: A critical review
JP2000044470A (en) Hyperlipemia medicine

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2005222706

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2005735088

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

ENP Entry into the national phase

Ref document number: 2005222706

Country of ref document: AU

Date of ref document: 20050317

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005222706

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2005735088

Country of ref document: EP